Note: Revised Decision Points for the Report of the Portfolio Committee (as drafted by the Portfolio Committee on 27 April 2006).

Summary of Decision Points:

Eligibility Criteria for Upper-Middle Income Countries

The Board decides that proposals from applicants whose economies are classified by the World Bank as “upper-middle income” may become eligible if:

a. the applicant falls under the “small island economy” exception to the International Development Association lending eligibility requirements, regardless of national disease burden; or

b. there is an HIV sero-prevalence rate of more than five percent in a vulnerable population in the country regardless of national disease burden, provided that:
   1. the proposal targets the vulnerable population;
   2. the applicant provides a definition of the vulnerable population, including the size of the population and evidence of the sero-prevalence rate within such population;
   3. the evidence provided by the applicant is validated by the WHO or UNAIDS; and
   4. they demonstrate counterpart financing with a progressive increase from 30 percent in Year 1 to 50 percent over the duration of the proposal.

This decision does not affect the applicability of counterpart financing and other eligibility requirements.

The Board requests the Portfolio Committee to review eligibility criteria for upper-middle income countries for Round 7.

Phase 2 Decision-Making Policies and Procedures

The Board decides to extend the application of the Phase 2 Decision-Making Policies and Procedures set out in Annex 1 to the Report of the Portfolio Committee to the Twelfth Board Meeting (GF/B12/6) and as amended at the Twelfth Board Meeting, beyond the trial period specified therein and to delete the final paragraph of such document.

The Board requests the Portfolio Committee to review the Phase 2 Decision-Making Policies and Procedures and develop recommendations for the Board to consider at its fourteenth meeting.

Green Light Committee

The Board recognizes the essential service provided by the Green Light Committee as a unique entity that ensures the quality of multi-drug resistant tuberculosis control programs. The Board reaffirms its decision taken at the Third Board Meeting, which requires recipients of Global Fund
grants to procure second-line anti-tuberculosis drugs through the Green Light Committee, and recognizes that the Green Light Committee provides a package of services for multi-drug resistant tuberculosis control treatment that cannot be disaggregated. The Board urges the Green Light Committee to develop a proactive resource-mobilization effort to attract other donor funding.

a) The Board decides that applicants:

   I. applying for grants with multi-drug resistant tuberculosis control components in Round 6 and beyond; or

   II. submitting a Request for Continued Funding for grants with multi-drug resistant tuberculosis control components as of January 2007,

must include a cost-sharing element for Green Light Committee services. To limit transaction costs, this will be defined by the Secretariat in consultation with the Green Light Committee as a flat rate per grant per year that will not exceed US$ 50,000 per grant per year. This figure is subject to review by the Portfolio Committee.

b) The Board requests the Secretariat to explore mechanisms to apply these cost-sharing principles for Green Light Committee services to programs funded by grants in Rounds 1 through 5 that are not already covered by paragraph (a) (ii) of this decision and report back to the Board at the Fourteenth Board Meeting.